Sign In
Buy MRK
$119.05
-1.73 (-1.43%)
At Close: Jun 12, 2026
Flavin Financial Services Inc. Boosts Stock Holdings in Merck & Co., Inc. $MRK
05:06am, Monday, 09'th Mar 2026
Flavin Financial Services Inc. raised its position in shares of Merck and Co., Inc. (NYSE: MRK) by 27.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exch
1 Dividend Stock to Buy Hand Over Fist and 1 to Avoid
01:30pm, Sunday, 08'th Mar 2026
Wall Street is enamored of pharmaceutical giant Eli Lilly and its GLP-1 products right now. This pharma peer has a a more modest P/E, more attractive yield, and a solid payout ratio.
Blair William & Co. IL Has $68.18 Million Stake in Merck & Co., Inc. $MRK
04:35am, Sunday, 08'th Mar 2026
Blair William and Co. IL lowered its stake in shares of Merck and Co., Inc. (NYSE: MRK) by 6.9% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 812,366 share
3 Undervalued Names Too Cheap to Ignore
08:49am, Saturday, 07'th Mar 2026
Highly publicized growth trajectories of some of the biggest companies out there may make it seem like 2026 is not a prime time for a value strategy. Still, some fairly sizable firms are trading at a
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (March 2026)
08:15am, Saturday, 07'th Mar 2026
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filter
First Trust Advisors LP Cuts Stake in Merck & Co., Inc. $MRK
04:56am, Saturday, 07'th Mar 2026
First Trust Advisors LP cut its holdings in shares of Merck and Co., Inc. (NYSE: MRK) by 0.8% during the third quarter, according to the company in its most recent filing with the Securities and Excha
Merck (MRK) Up 1.7% Since Last Earnings Report: Can It Continue?
12:35pm, Thursday, 05'th Mar 2026
Merck (MRK) reported earnings 30 days ago. What's next for the stock?
Forget ImmunityBio: This Big‑Cap Pharma Is the Safer Play on Next‑Gen Cancer Therapies
10:00am, Thursday, 05'th Mar 2026
ImmunityBio's recently approved cancer drug has plenty of momentum. However, valuation concerns and clinical and regulatory uncertainty make the stock risky.
5 of Bank of America's US1 List Top Picks Also Pay Big Passive Income
07:48am, Thursday, 05'th Mar 2026
Most dividend investors seek solid passive income streams from quality dividend stocks.
CALABASAS, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company deve
Merck & Co., Inc. (MRK) Presents at TD Cowen 46th Annual Health Care Conference Transcript
03:42pm, Tuesday, 03'rd Mar 2026
Merck & Co., Inc. (MRK) Presents at TD Cowen 46th Annual Health Care Conference Transcript
AI-Powered Tempus Inks New Multi-Year Merck Deal
02:33pm, Tuesday, 03'rd Mar 2026
Tempus AI Inc. (NASDAQ: TEM) on Tuesday inked a strategic collaboration agreement with Merck & Co. Inc. (NYSE: MRK) aimed at accelerating AI-driven precision medicine.
Most Retirees Overlook These Dow Dividend Stocks — They Pay More Than You'd Expect
12:49pm, Tuesday, 03'rd Mar 2026
The Dow Jones Industrial Average, commonly just called the Dow Jones or the Dow, includes 30 giant publicly listed companies with U.S.
Merck's Keytruda Drives its 2025 Revenue Surge: What's Ahead?
11:06am, Tuesday, 03'rd Mar 2026
Merck MRK has a strong foothold in the oncology market, primarily supported by its biggest revenue driver, Keytruda. The blockbuster PD-1 inhibitor accounts for around 55% of the company's pharmaceu
Merck (MRK) Stock Dips While Market Gains: Key Facts
06:45pm, Monday, 02'nd Mar 2026
In the latest trading session, Merck (MRK) closed at $121.41, marking a -1.95% move from the previous day.
